Establishment of a biomarker to test molecular risk of Gastric Cancer
Grant number: 1030980 | Funding period: 2012 - 2015
Less than 20% of patients live 5 years after a diagnosis of gastric cancer (GC). This is due to the advanced stage at the time of diagnosis. We have no markers to monitor therapy of cancer. This proposal aims to use next generation sequencing to find specific genetic changes in a persons tumour that can be used to monitor therapy. We aim to use the same technology to group patients into high-risk or low risk for development of GC. This will allow specific screening only for those at high-risk.
Related publications (2)
SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence
Rita A Busuttil, Joshy George, Colin M House, Stephen Lade, Catherine Mitchell, Natasha S Di Costanzo, Sharon Pattison, Yu-Kuan Huang, Patrick Tan, Jae-Ho Cheong, Sun Young Rha, Alex Boussioutas
OBJECTIVE: Gastric cancer patients generally have a poor outcome, particularly those with advanced-stage disease which is defined ..
Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer
Sharon Pattison, Catherine Mitchell, Stephen Lade, Trevor Leong, Rita A Busuttil, Alex Boussioutas
BACKGROUND: Survival from gastric cancer remains poor, particularly in Western populations. Previous pre-clinical and subgroup ana..